Cargando…
Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
Abrishami, Oortwijn, and Hofman (AOH) attribute to me a position I do not hold and an argument I did not make. The purpose of this note is make clear what my position actually is and to clarify the main differences between health technology assessment (HTA) and cost-effectiveness analysis (CEA).
Autor principal: | Culyer, Anthony J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kerman University of Medical Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885861/ https://www.ncbi.nlm.nih.gov/pubmed/31779302 http://dx.doi.org/10.15171/ijhpm.2019.73 |
Ejemplares similares
-
Ethics in HTA: Examining the "Need for Expansion"
por: Abrishami, Payam, et al.
Publicado: (2017) -
The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018) -
Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023) -
The Need for Global Application of the Accountability for Reasonableness Approach to Support Sustainable Outcomes: Comment on "Expanded HTA: Enhancing Fairness and Legitimacy"
por: Byskov, Jens, et al.
Publicado: (2016) -
Ethical analysis in HTA of complex health interventions
por: Lysdahl, Kristin Bakke, et al.
Publicado: (2016)